Drug intelligence / Profile preview

alteplase + ranibizumab

Development stage: Unknown
Lead developer: Genentech
Modality: Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
Administration: Intravitreal

Overview

A combination therapy consisting of alteplase (recombinant tissue plasminogen activator) and ranibizumab. Alteplase is a thrombolytic agent that cleaves plasminogen to form plasmin, which degrades fibrin clots. Ranibizumab is a recombinant humanized monoclonal antibody fragment that targets vascular endothelial growth factor A (VEGF-A). When used together, alteplase helps break down fibrin and fibrovascular tissue while ranibizumab inhibits neovascularization. This combination has shown synergistic effects in treating subfoveal type 2 choroidal neovascularization and submacular hemorrhage in age-related macular degeneration.

Other names: tissue plasminogen activator + ranibizumabtPA + ranibizumabrtPA + ranibizumab

Targets

VEGFA (Vascular endothelial growth factor A)PLG (Plasminogen)

Beyond the preview

Go deeper on alteplase + ranibizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on alteplase + ranibizumab.

Explore the full profile